{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:41Z","timestamp":1740106901218,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00277-021-04692-9","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T17:56:55Z","timestamp":1634752615000},"page":"335-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase 1 trial of carfilzomib in relapsed\/refractory peripheral T-cell lymphoma"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-5219","authenticated-orcid":false,"given":"Mridula","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Gregory","family":"Bociek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Bierman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avyakta","family":"Kallam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"issue":"5151","key":"4692_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science 263(5151):1281\u20131284","journal-title":"Science"},{"issue":"3","key":"4692_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood.V89.3.948","volume":"89","author":"K Tsukasaki","year":"1997","unstructured":"Tsukasaki K, Tsushima H, Yamamura M, Hata T, Murata K, Maeda T et al (1997) Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 89(3):948\u2013956","journal-title":"Blood"},{"issue":"4","key":"4692_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/hon.786","volume":"24","author":"T R\u00fcdiger","year":"2006","unstructured":"R\u00fcdiger T, Geissinger E, M\u00fcller-Hermelink HK (2006) \u2018Normal counterparts\u2019 of nodal peripheral T-cell lymphoma. Hematol Oncol 24(4):175\u2013180","journal-title":"Hematol Oncol"},{"issue":"16","key":"4692_CR4","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472\u20132479","journal-title":"J Clin Oncol"},{"issue":"25","key":"4692_CR5","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"JM Vose","year":"2008","unstructured":"Vose JM, Weisenburger DD, Armitage JO et al (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130","journal-title":"J Clin Oncol"},{"issue":"12","key":"4692_CR6","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","volume":"19","author":"B Martinez-Delgado","year":"2005","unstructured":"Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J et al (2005) Differential expression of NF-\u03baB pathway genes among peripheral T-cell lymphomas. Leukemia 19(12):2254","journal-title":"Leukemia"},{"issue":"11","key":"4692_CR7","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109(11):4952\u20134963","journal-title":"Blood"},{"issue":"22","key":"4692_CR8","doi-asserted-by":"publisher","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","volume":"67","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S et al (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67(22):10703\u201310710","journal-title":"Cancer Res"},{"key":"4692_CR9","doi-asserted-by":"crossref","unstructured":"MLAPiccaluga Pier-Paolo, et al. (2005) \u201cGene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existance of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.\u201d \u00a01217\u20131217","DOI":"10.1182\/blood.V106.11.1217.1217"},{"issue":"22","key":"4692_CR10","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","volume":"25","author":"M Cuadros","year":"2007","unstructured":"Cuadros M, Dave SS, Jaffe ES, Honrado E, Milne R, Alves J et al (2007) Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 25(22):3321\u20133329","journal-title":"J Clin Oncol"},{"issue":"5","key":"4692_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115(5):1026\u20131036","journal-title":"Blood"},{"issue":"2","key":"4692_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11899-006-0024-5","volume":"1","author":"J Iqbal","year":"2006","unstructured":"Iqbal J, d\u2019Amore F, Hu Q, Chan WC, Fu K (2006) Gene arrays in lymphoma: where will they fit in? Curr Hematol Malig Rep 1(2):129\u2013136","journal-title":"Curr Hematol Malig Rep"},{"issue":"10168","key":"4692_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229\u2013240","journal-title":"Lancet"},{"issue":"14","key":"4692_CR14","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817\u20132825","journal-title":"Blood"},{"issue":"3","key":"4692_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1172\/JCI26833","volume":"117","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S et al (2007) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117(3):823\u2013834","journal-title":"J Clin Invest"},{"issue":"4","key":"4692_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","volume":"72","author":"KP Papadopoulos","year":"2013","unstructured":"Papadopoulos KP, Burris HA, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE, Wang Z, Lee S, Jones SF (2013) A phase I\/II study of carfilzomib 2\u201310-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 72(4):861\u2013868","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4692_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11899-006-0024-5","volume":"1","author":"J Iqbal","year":"2006","unstructured":"Iqbal J, d\u2019Amore F, Hu Q, Chan WC, Fu K (2006) Gene arrays in lymphoma: where will they fit in? Curr Hematol Malig Rep 1(2):129\u2013136","journal-title":"Curr Hematol Malig Rep"},{"key":"4692_CR18","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho A et al (2010) Treatment and prognosis of nature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-hodgkin lymphoma study group. Blood 116:3418\u20133425","journal-title":"Blood"},{"issue":"6","key":"4692_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","volume":"44","author":"ES Wang","year":"2003","unstructured":"Wang ES, O\u2019Connor O, She Y, Zelenetz AD, Sirotnak F, Moore MA (2003) Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44(6):1027\u20131035","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"4692_CR20","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22):5827\u20135834","journal-title":"Blood"},{"issue":"20","key":"4692_CR21","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA et al (2014) Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123(20):3095\u20133100","journal-title":"Blood"},{"issue":"23","key":"4692_CR22","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492\u20132499","journal-title":"J Clin Oncol"},{"key":"4692_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","volume":"131","author":"JE Amengual","year":"2018","unstructured":"Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E et al (2018) A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 131:397\u2013407","journal-title":"Blood"},{"issue":"22","key":"4692_CR24","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1182\/blood.V128.22.2991.2991","volume":"128","author":"N Mehta-Shah","year":"2016","unstructured":"Mehta-Shah N, Moskowitz AJ, Lunning M, Lynch P, Scheuerman M, Kumar A et al (2016) A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas. Blood 128(22):2991","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04692-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T09:03:36Z","timestamp":1641632616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04692-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4692"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04692-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"25 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Mridula Krishnan\u00a0has no conflict of interest.R.Gregory Bociek\u00a0is on the data safety and monitoring committee for Innate Pharma.Michelle Fanale has no conflict of interest.Swaminathan P. Iyer, researcher, Seagen, Crisprx, Innate, Trillium, Merck, Acrotech, and Legend; speaker, Curio Bioscience and Targeted Oncology.Mary Jo Lechowicz has no conflict of interest.Philip J. Bierman has no conflict of interest.James O. Armitage is on the board\u00a0of\u00a0Cardiff Oncology and an advisor to Acentage Pharma and Samus Therapeutics.Matthew Lunning, BeiGene, Karyopharm, Gilead\/Kite Daiichi-Sankyo, Novartis, Kyowa Kirin, AbbVie, Celgene, a Bristol Myers Squibb Co., Verastem, Janssen, Myeloid Therapeutics, AstraZeneca, Acrotech, ADC Therapeutics, Legend, Spectrum, BeiGene, Daiichi-Sankyo, MorphoSys, TG Therapeutics.Avyakta Kallam has no conflict of interest.Julie M.Vose research grant support, Acerta\/AstraZeneca, Celgene\/BMS, Incyte Corp., Kite Pharma, Novartis, Seattle Genetics, Inc., LOXO; consulting\/honorarium, Abbvie, Vaniam Group, Janssen\/Pharmacyclics, Kite Pharma, Acerta\/AstraZeneca, Roche, Genentech, MorphoSys, Conjupro Biotherapeutics, Oncternal, and Johnson and Johnson.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}